Yuankai Shi
A medical oncologist who has led many of China's registrational trials of domestically developed targeted agents and antibodies.
Yuankai Shi has been principal investigator for Chinese phase 3 trials of EGFR inhibitors, PD-1 antibodies, and lymphoma therapies, and leads the hospital's clinical pharmacology and drug development programme.
Pages like this
not linked directly; found by shared links- PersonJie He
Shares Cancer Hospital, Chinese Academy of Medical Sciences, Non-small-cell lung cancer.
- PersonJie Wang
Shares Cancer Hospital, Chinese Academy of Medical Sciences, Non-small-cell lung cancer.
- InstitutionHenan Cancer Hospital
Shares Diffuse large B-cell lymphoma, Non-small-cell lung cancer.
- PersonAsh A. Alizadeh
Shares Diffuse large B-cell lymphoma, Non-small-cell lung cancer.
- InstitutionRajiv Gandhi Cancer Institute and Research Centre
Shares Diffuse large B-cell lymphoma, Non-small-cell lung cancer.
- InstitutionNational University Hospital / National University Cancer Institute, Singapore
Shares Diffuse large B-cell lymphoma, Non-small-cell lung cancer.
- InstitutionKing Hussein Cancer Center
Shares Diffuse large B-cell lymphoma, Non-small-cell lung cancer.
- InstitutionInstituto Nacional de Cancerología (Mexico)
Shares Diffuse large B-cell lymphoma, Non-small-cell lung cancer.